Abstract
Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non-TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression-free survival with post-ICB treatment (median, 17.5 months vs. 6.1 months, p =.035) and longer time-to-subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p =.003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.
Original language | English (US) |
---|---|
Pages (from-to) | e993-e997 |
Journal | Oncologist |
Volume | 25 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2020 |
ASJC Scopus subject areas
- General Medicine